Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriGlytza
- Development stage
- Phase 2
- Lead developer
- Myopharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TriGlytza is an oral combination therapy developed by Myopharm Limited for the treatment of type 2 diabetes mellitus (T2DM). It is a fixed-dose combination consisting of three small molecule drugs: celecoxib (a COX-2 inhibitor), valsartan (an angiotensin receptor blocker), and metformin (a biguanide). The therapy is specifically designed to target multiple distinct and overlapping pro-inflammatory signaling pathways along the RAS-IL1b-Cox2-PGE2-EP3 axes. These pathways are implicated in the progressive deterioration of pancreatic beta cell function and the development of insulin resistance, which are the core defects in T2DM. By addressing these underlying inflammatory drivers, TriGlytza aims to preserve beta cell mass and improve glycemic control more effectively than metformin monotherapy. It is currently being evaluated in Phase II clinical trials in Australia and the United States.
- Brand names
- TriGlytza
- Other names
- RK-01RK01RK 01
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on TriGlytza.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriGlytza.